Health
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
SAN DIEGO, January 13, 2026--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026.
About this update from Travere Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1604,"height":352,"url":"https://media.zenfs.com/en/business-wire.com/61111f2327acd8210aee35a522b7faa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/44RGLO1lmZBxLXJJ3tb6mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/61111f2327acd8210aee35a522b7faa6","width":960,"height":211},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ynF6rkBYRVXYl7alHZwmLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/61111f2327acd8210aee35a522b7faa6","width":1200,"height":263}},"lazy":false},{"type":"text","content":"New PDUFA target action date is April 13, 2026","length":46,"tagName":"p","attribs":{}},{"type":"text","content":"Commercial launch preparations continue in anticipation of potential approval","length":77,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, January 13, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026.","length":392,"tagName":"p"},{"type":"text","content":"The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI. The FDA determined that the additional responses constituted a Major Amendment (MA) to the sNDA and extended the action date accordingly. No additional information relating to the safety or manufacturing of FILSPARI has been requested.","length":371,"tagName":"p"},{"type":"text","content":""We believe in the potential of FILSPARI to make a meaningful difference in the lives of people living with FSGS and are encouraged by the productive engagement with the FDA," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. "We remain focused on the goal of bringing FILSPARI to the patients who urgently need an effective medicine for this devastating and rapidly progressing disease and remain committed to working with the Agency during...